Allo HSCT for High Risk Hemoglobinopathies
Phase 2
62
about 7.5 years
≤55
1 site in MN
About this study
Researchers are testing a treatment called allogeneic hematopoietic stem cell transplantation (HSCT) for people with high-risk hemoglobinopathies and other conditions that require frequent blood transfusions. The trial will involve using various medications, including chemotherapy drugs, to prepare the patient before the transplant.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Cell Infusion
- 2.Receive Total Body Irradiation
- 3.Take Alemtuzumab
- +3 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
alemtuzumab, busulfan, cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), fludarabine, Immunological Agents (Enzyme Inhibitors), sirolimus, tacrolimus, thiotepa
injection (Injection), injection, intravenous, infusion
Secondary: Overall Survival
radiation